Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708194 | 0.88 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL16708170 | 0.88 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL15349722 | 0.84 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL16708107 | 0.84 | F2RL3 (0.80) | F2RL3 | |
| SCHEMBL15359232 | 0.84 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL16708169 | 0.84 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL16708168 | 0.84 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL16708144 | 0.84 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL16708237 | 0.82 | F2RL3 (1.00) | F2RL3 | |
| SCHEMBL16708150 | 0.82 | F2RL3 (1.00) | F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862730-B2 | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2847200-B1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | F2RL3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.